Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 389 for:    CLARITHROMYCIN

Clarithromycin in Multiple Myeloma Induction Therapy (CLAIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02573935
Recruitment Status : Terminated (Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone))
First Posted : October 12, 2015
Last Update Posted : September 20, 2016
Sponsor:
Collaborator:
Danish Myeloma Study Group
Information provided by (Responsible Party):
Henrik Gregersen, Aalborg University Hospital

Brief Summary:
This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Clarithromycin Drug: Placebo Drug: VCD induction therapy Phase 2

Detailed Description:

The survival in younger myeloma patients improved in the nineties with the introduction of high-dose melphalan with autologous stem cell support (HDT). However, all patients will eventually experience relapse after HDT and there is a need for improvement of the response after HDT. The choice of induction treatment before HDT affects the outcome after induction therapy as well as the outcome after HDT.

Clarithromycin is a macrolide antibiotic frequently utilized in the treatment of respiratory tract infections and is often used in patients with known hypersensitivity to beta-lactam antibiotic. Besides antibiotic activity, clarithromycin may exert immunomodulatory and anti-inflammatory effects. The toxicity profile of clarithromycin is favourable and the cost is very low.

Studies on cell lines have shown that clarithromycin attenuates autophagy in myeloma cells and a recent study has demonstrated that treatment with clarithromycin enhanced bortezomib-induced cytotoxicity in myeloma cells. Phase II studies without control groups have indicated that clarithromycin might enhance the effect of the thalidomide and lenalidomide. A case-matched analysis compared patients at one centre receiving clarithromycin, lenalidomide and dexamethasone with an equal number of patients at another centre receiving lenalidomide and dexamethasone. This study indicated a favourable effect of clarithromycin with a higher frequency of complete response, very-good-partial-response or better response and progression-free survival. However, there is a need for controlled studies to determine whether clarithromycin might enhance the effect of other myeloma agents.

This randomized placebo-controlled study will include 160 patients with newly diagnosed multiple myeloma eligible for HDT. The study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma, and is conducted by the Danish Myeloma Study Group (DMSG) at seven clinics in Denmark. The first patient was included in May 2015 and enrolment is expected to continue until October 2016. The study ends when the last included patient has been followed for two months after HDT.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma
Study Start Date : January 2015
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Clarithromycin
Clarithromycin combined with VCD induction therapy
Drug: Clarithromycin
p.o. clarithromycin 500 mg twice daily for 63 days

Drug: VCD induction therapy
Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)

Placebo Comparator: Placebo
Placebo combined with VCD induction therapy
Drug: Placebo
Placebo tablet twice daily for 63 days

Drug: VCD induction therapy
Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)




Primary Outcome Measures :
  1. Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo [ Time Frame: 10 weeks ]

Secondary Outcome Measures :
  1. Comparison of number of participants with very good partial response or better response after HDT in patients treated with three courses of VCD combined with clarithromycin or placebo [ Time Frame: Five months ]
  2. Comparison of number of participants with sCR, CR, PR, PD or SD in the treatment groups after induction therapy and HDT, respectively [ Time Frame: Five months ]
  3. Comparison of frequency of infections in patients treated VCD combined with clarithromycin or placebo [ Time Frame: 9 weeks ]
  4. Comparison of number of stem cells harvested in patients treated with clarithromycin and placebo in combination with VCD [ Time Frame: Three months ]
  5. Neurotoxicity assessed by FACT/GOG-Ntx, Version 4.0 [ Time Frame: Five months ]
  6. Quality of life assessed by EORTC QLQ-MY20 [ Time Frame: Five months ]
  7. Quality of life assessed by EORTC QLQ-C30 [ Time Frame: Five months ]
  8. Comparison of adverse events in patients treated VCD combined with clarithromycin or placebo assessed by CTCAE v4.0 [ Time Frame: Three months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Myeloma diagnosis according to IMWG criteria
  • Treatment demanding disease
  • High-dose melphalan with stem cell support scheduled as a part of the treatment
  • Signed informed consent given prior to any study related activities
  • Age > 18 years

Exclusion Criteria:

  • Allogeneic transplantation scheduled as a part of the treatment
  • Myeloma treatment prior to entry in the study, except radiotherapy, bisphosphonates/denosumab or corticosteroids for symptom control
  • Concurrent disease making clarithromycin treatment unsuitable
  • Positive pregnancy test (only applicable for women with childbearing potential)
  • Known or suspected hypersensitivity or intolerance to clarithromycin
  • Prolonged QT corrected (QTc) interval ( > 500 msec on screening ECG)
  • Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide, quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin or other statins
  • Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, uncontrolled angina or known cardiac amyloidosis
  • Severe renal dysfunction (estimated creatinine clearance <10 mL/min)
  • Serious medical or psychiatric illness which, in the judgment of the investigator, would make the patient inappropriate for entry into the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02573935


Locations
Layout table for location information
Denmark
Department of Hematology, Aalborg University Hospital
Aalborg, Denmark, 9000
Department of Hematology, Aarhus University Hospital
Aarhus, Denmark, 8000
Department of Hematology, Rigshospitalet
Copenhagen, Denmark, 2100
Department of Hematology, Herlev Hospital
Herlev, Denmark, 2730
Department of Hematology, Odense University Hospital
Odense, Denmark, 5000
Department of Hematology, Roskilde Hospital
Roskilde, Denmark, 4000
Department of Hematology, Vejle Hospital
Vejle, Denmark, 7100
Sponsors and Collaborators
Henrik Gregersen
Danish Myeloma Study Group
Investigators
Layout table for investigator information
Principal Investigator: Henrik Gregersen, MD Aalborg University Hospital

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Henrik Gregersen, Consultant, Aalborg University Hospital
ClinicalTrials.gov Identifier: NCT02573935     History of Changes
Other Study ID Numbers: DMSG 03/14
2014-002187-32 ( EudraCT Number )
First Posted: October 12, 2015    Key Record Dates
Last Update Posted: September 20, 2016
Last Verified: September 2016
Keywords provided by Henrik Gregersen, Aalborg University Hospital:
Multiple Myeloma
Clarithromycin
Induction Chemotherapy
Transplantation, Autologous
Additional relevant MeSH terms:
Layout table for MeSH terms
Clarithromycin
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors